HDFC Pharma and Healthcare Fund - Growth Option
HDFC Mutual Fund · Managed by Nikhil Mathur
₹19.3050
₹0.08 (-0.42%)
NAV as of 29 May 2026
Today's NAV — all variants
Regular · Growth
₹₹19.3050
₹0.08 (-0.42%)
29 May 2026
AMFI: 152084
Direct · Growth
₹₹19.9280
₹0.08 (-0.41%)
29 May 2026
AMFI: 152082
Regular · IDCW
₹₹19.3050
₹0.08 (-0.42%)
29 May 2026
AMFI: 152083
Direct · IDCW
₹₹19.9280
₹0.08 (-0.41%)
29 May 2026
AMFI: 152081
Returns (Lumpsum)
CAGR for periods ≥ 1 yearSIP Returns (XIRR)
₹1,000/month SIP, annualisedSIP since inception — what ₹100/month became
Real NAV backtest from day one
₹3,100
Invested
₹4,041
Value today
21.2%
XIRR (p.a.)
₹100/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹100 lumpsum at launch — value today
Invested on the fund's first NAV date
₹100
Invested
₹193
Value today
28.2%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹9,84,152
Value today
-15.0%
vs lumpsum
Direct lumpsum would have beaten STP by 15.0% — but STP reduced timing risk
Model your own STP with real NAVBeat the benchmark — ₹100/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹4,041
Benchmark
₹3,626
+₹415 extra wealth vs the benchmark index
Backtest this SIP yourselfDirect vs Regular — ₹500/month over 2 years
Expense ratio drag on your actual returns
Direct plan
₹15,323
Regular plan
₹15,123
Direct earns ₹200 more on a ₹12K investment — 0.83% extra return per year
Same fund, same NAV history — only the expense ratio differs. Direct plans always outperform Regular over time.
Learn about Direct vs Regular plansFund Details
Risk Metrics
Trailing 1 year, annualised0.41
Sharpe Ratio
+0.09
Alpha
0.36
Beta
0.38
Sortino
15.76%
Std Dev
-15.07%
Max Drawdown
Portfolio Holdings
Top 50 holdings · as of Mar 2026
| Security | % NAV |
|---|---|
Sun Pharmaceutical Industries Ltd. INE044A01036 | 10.20% |
Divis Laboratories Ltd. INE361B01024 | 8.56% |
Divis Laboratories Ltd. INE361B01024 | 8.20% |
Sun Pharmaceutical Industries Ltd. INE044A01036 | 8.05% |
Glenmark Pharmaceuticals Ltd. INE935A01035 | 6.78% |
Lupin Ltd. INE326A01037 | 6.65% |
Lupin Ltd. INE326A01037 | 6.07% |
Glenmark Pharmaceuticals Ltd. INE935A01035 | 6.06% |
Alkem Laboratories Ltd. INE540L01014 | 5.99% |
Max Healthcare Institute Limited INE027H01010 | 5.96% |
Max Healthcare Institute Limited INE027H01010 | 5.93% |
Aster DM Healthcare Limited INE914M01019 | 5.70% |
Aster DM Healthcare Limited INE914M01019 | 5.46% |
Ipca Laboratories Ltd. INE571A01038 | 5.16% |
Alkem Laboratories Ltd. INE540L01014 | 4.69% |
Anthem Biosciences Limited INE0CZ201020 | 4.55% |
Ipca Laboratories Ltd. INE571A01038 | 4.39% |
Acutaas Chemicals Limited INE00FF01025 | 4.39% |
Anthem Biosciences Limited INE0CZ201020 | 4.29% |
Cipla Ltd. INE059A01026 | 4.27% |
Acutaas Chemicals Limited INE00FF01025 | 4.07% |
Fortis Healthcare Limited INE061F01013 | 3.71% |
Fortis Healthcare Limited INE061F01013 | 3.49% |
Krishna Institute Of Medical Sciences Limited INE967H01025 | 3.10% |
Krishna Institute Of Medical Sciences Limited INE967H01025 | 3.04% |
Laurus Labs Ltd. INE947Q01028 | 2.80% |
Laurus Labs Ltd. INE947Q01028 | 2.76% |
Vijaya Diagnostic Centre Limited INE043W01024 | 2.55% |
Metropolis Healthcare Ltd. INE112L01020 | 2.39% |
Metropolis Healthcare Ltd. INE112L01020 | 2.37% |
Torrent Pharmaceuticals Ltd. INE685A01028 | 2.34% |
Eris Lifesciences Ltd INE406M01024 | 2.24% |
Global Health Limited INE474Q01031 | 2.21% |
Vijaya Diagnostic Centre Limited INE043W01024 | 2.13% |
Torrent Pharmaceuticals Ltd. INE685A01028 | 2.13% |
Sai Life Sciences Limited INE570L01029 | 2.09% |
Shilpa Medicare Ltd INE790G01031 | 2.04% |
Neuland Laboratories Limited INE794A01010 | 1.97% |
Shilpa Medicare Ltd INE790G01031 | 1.91% |
Global Health Limited INE474Q01031 | 1.88% |
Sai Life Sciences Limited INE570L01029 | 1.79% |
Wockhardt Ltd. INE049B01025 | 1.67% |
Eris Lifesciences Ltd INE406M01024 | 1.66% |
Dr. Lal Path Labs Ltd INE600L01024 | 1.57% |
Wockhardt Ltd. INE049B01025 | 1.54% |
Neuland Laboratories Limited INE794A01010 | 1.54% |
Rubicon Research Limited INE506V01022 | 1.43% |
Jubilant Pharmova Limited INE700A01033 | 1.36% |
Thyrocare Technologies Ltd. INE594H01019 | 1.33% |
Jubilant Pharmova Limited INE700A01033 | 1.31% |
Performance Comparison
Interested in This Fund?
Our experts will help you decide if this fund fits your goals.
Compare with Similar Funds
Investment Objective
HDFC Pharma and Healthcare Fund - Growth Option invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
HDFC Pharma and Healthcare Fund - Growth Option is a Sectoral / Thematic mutual fund offered by HDFC Mutual Fund. The fund has been operational for over 2 years. It manages assets worth ₹1,963 Cr, reflecting investor confidence in the fund's strategy. The fund is managed by Nikhil Mathur. It benchmarks its performance against BSE Healthcare Index (TRI). The current expense ratio is 2.09%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations